Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
155 results
  • Canakinumab for the treatment of hyperimmunoglobulin D syndrome. [Journal Article]
    Expert Rev Clin Immunol 2019; 15(3):215-220Sánchez-Manubens J, Iglesias E, Anton J
  • Mevalonate Kinase Deficiency (MKD) is a rare monogenic autoinflammatory disorder (AID) with autosomal recessive inheritance caused by mutations in the MVK gene. It includes hyperimmunoglobulinemia D syndrome (HIDS) and mevalonic aciduria (a severe form). Patients have recurrent inflammatory attacks with high fever, gastrointestinal symptoms, lymphadenopathy, splenomegaly, arthralgia, rash, pharyn…
  • Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA. [Review]
    Dermatol Ther (Heidelb) 2018; 8(4):539-556Gómez-García F, Sanz-Cabanillas JL, … Ruano J
  • CONCLUSIONS: Evidence on use of anti-IL-1 drugs in DIRA and DITRA is scarce and based on observational studies. Larger studies with better methodological quality are needed to increase confidence in use of these drugs in patients with DIRA and DITRA.
  • Interventions for reducing inflammation in familial Mediterranean fever. [Meta-Analysis]
    Cochrane Database Syst Rev 2018; 10:CD010893Wu B, Xu T, … Yin X
  • CONCLUSIONS: There were limited RCTs assessing interventions for people with familial Mediterranean fever. Based on the evidence, three times daily colchicine appears to reduce the number of people experiencing attacks, colchicine single dose and divided dose might not be different for children with familial Mediterranean fever and anakinra might reduce C-reactive protein in colchicine-resistant participants; however, only a few RCTs contributed data for analysis. Further RCTs examining active interventions, not only colchicine, are necessary before a comprehensive conclusion regarding the efficacy and safety of interventions for reducing inflammation in familial Mediterranean fever can be drawn.
  • Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. [Review]
    Curr Treat Options Neurol 2018; 20(10):43Keddie S, Parker T, … Ginsberg L
  • The purpose of this review is to highlight the molecular and clinical characteristics of the cryopyrin-associated periodic fever syndrome (CAPS) and its management. CAPS is an autosomal dominantly inherited autoinflammatory disorder associated with mutations in the NLRP3 gene, which ultimately lead to excessive production of interleukin-1β (IL-1β) and systemic inflammation. Typical systemic featu…
  • The Future of IL-1 Targeting in Kidney Disease. [Review]
    Drugs 2018; 78(11):1073-1083Afsar B, Covic A, … Kanbay M
  • Interleukin (IL)-1α and IL-1β are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1β antibodies (canakinumab) and IL-1β traps (rilonacep…
  • The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. [Review]
    Drug Des Devel Ther 2018; 12:1633-1643Toplak N, Blazina Š, Avčin T
  • The pathogenesis, clinical course, and response to treatment in systemic juvenile idiopathic arthritis (SJIA) differ from other types of juvenile idiopathic arthritis and are similar to other interleukin-1 (IL-1)-mediated diseases. The main cytokine involved in the pathogenesis of SJIA is IL-1β, which can be neutralized by targeted anti-IL-1 therapy. In SJIA, no antibodies have been found and the…
New Search Next